Logo do repositório
 
Publicação

Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024

datacite.subject.fosCiências Médicas
datacite.subject.sdg03:Saúde de Qualidade
datacite.subject.sdg17:Parcerias para a Implementação dos Objetivos
dc.contributor.authorAntunes, Liliana
dc.contributor.authorRojas-Castro, Madelyn
dc.contributor.authorLozano, Marcos
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorLeroux-Roels, Isabel
dc.contributor.authorBorg, Maria-Louise
dc.contributor.authorOroszi, Beatrix
dc.contributor.authorFitzgerald, Margaret
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorJancoriene, Ligita
dc.contributor.authorMachado, Ausenda
dc.contributor.authorPetrović, Goranka
dc.contributor.authorLazar, Mihaela
dc.contributor.authorSoučková, Lenka
dc.contributor.authorBacci, Sabrina
dc.contributor.authorHoward, Jennifer
dc.contributor.authorVerdasca, Nuno
dc.contributor.authorBasile, Luca
dc.contributor.authorCastilla, Jesús
dc.contributor.authorTernest, Silke
dc.contributor.authorDžiugytė, Aušra
dc.contributor.authorTúri, Gergő
dc.contributor.authorDuffy, Roisin
dc.contributor.authorHackmann, Carolin
dc.contributor.authorKuliese, Monika
dc.contributor.authorGomez, Verónica
dc.contributor.authorMakarić, Zvjezdana Lovrić
dc.contributor.authorMarin, Alexandru
dc.contributor.authorHusa, Petr
dc.contributor.authorNicolay, Nathalie
dc.contributor.authorRose, Angela M. C.
dc.contributor.authorVEBIS SARI VE network team
dc.date.accessioned2026-01-13T13:15:18Z
dc.date.available2026-01-13T13:15:18Z
dc.date.issued2025-03-09
dc.descriptionVEBIS SARI VE network team: Portugal: Ana Paula Rodrigues, Débora Pereira, Margarida Tavares, Susana Costa Maia e Silva, Paula Pinto, Cristina Bárbara, António Pais de Lacerda, Raquel Guiomar, Camila Henriques.
dc.description.abstractWe estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.eng
dc.description.sponsorshipThe ‘Vaccine Effectiveness, Burden and Impact Studies’ (VEBIS) is a project of the European Centre for Disease Prevention and Control (ECDC) run under the framework contract No. ECDC/2021/016 (EU-H)
dc.identifier.citationInfluenza Other Respir Viruses. 2025 Mar;19(3):e70081. doi: 10.1111/irv.70081
dc.identifier.doi10.1111/irv.70081
dc.identifier.eissn1750-2659
dc.identifier.issn1750-2640
dc.identifier.pmid40059069
dc.identifier.urihttp://hdl.handle.net/10400.18/10687
dc.language.isoeng
dc.peerreviewedyes
dc.publisherWiley
dc.relation.hasversionhttps://onlinelibrary.wiley.com/doi/10.1111/irv.70081
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCase–Control Study
dc.subjectElderly
dc.subjectSevere Acute Respiratory Infections (SARI)
dc.subjectTest-Negative Design
dc.subjectVaccine Effectiveness
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectEurope
dc.subjectInfecções Respiratórias
dc.subjectDeterminantes da Saúde e da Doença
dc.subjectEstados de Saúde e de Doença
dc.titleEffectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024eng
dc.typejournal article
dcterms.referenceshttps://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Firv.70081&file=irv70081-sup-0001-Supporting_Information.docx
dspace.entity.typePublication
oaire.citation.issue3
oaire.citation.startPagee70081
oaire.citation.titleInfluenza and Other Respiratory Viruses
oaire.citation.volume19
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
IRV-19-e70081.pdf
Tamanho:
525.7 KB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição: